On Sunday, the genetic test and heritage company 23andme Declare She entered Chapter 11 bankruptcy and was asking the court to arrange its sale. The company was losing money for years, and it has led a conflict between the Board of Directors and the CEO on future trends Full resignation board Again in September. The CEO, CEO, Ann Wajiki, resigned, and will follow an attempt to buy the company and make it private.
At stake is the fate of the genetic data of the 15 million customers’ client. The company got enough financing to continue operations while finding the buyer, and although American law limits how genetic data is used, the suspended sale raised great special concerns.
Risk works
The company recently launched that “genetic chips” first allowed people to examine the human genome on a large scale for sites where the differences were common. A few of these variables are associated with diseases, and 23andme receives approval to test a number of these. But its great selling point for many people was the opportunity to explore their heritage. This relied on a wide range of contrast patterns and comparing those patterns usually in different geographical regions. It is an incomplete analysis, but it often may provide a great solution of a person’s ancestors.
23andme has faced a number of challenges. For beginners, genetic chips soon became goods, allowing a large group of competitors to enter this field, some of which had stronger backgrounds in things such as linking genealogy to public records. This commodity also means that many of the potential 23ndme partners in the pharmaceutical industry, who may be interested in genes/diseases, can build their databases or simply depend on some of the public resources that have been developed since then, such as The biological bank in the United Kingdom.